PASADENA, Calif. --(BUSINESS WIRE)--Jul. 14, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2021 , at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2021 .
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 14, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 1, 2021 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 42
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 6, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim results from the first two cohorts of AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 2, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today notified regulatory agencies, institutional review boards, and investigators that effective immediately it is voluntarily pausing AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the company’s
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 30, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROANG3-2001, a Phase 2b clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 26, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented additional positive interim 48-week liver biopsy results from the ongoing AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 25, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data on the development of ARO-DUX4, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with facioscapulohumeral
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 23, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented positive interim results from AROHSD1001, an ongoing Phase 1/2 clinical study of ARO-HSD, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
- Arrowhead to receive $40 million upfront payment - Horizon to receive a worldwide exclusive license for an investigational short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase (XDH) PASADENA, Calif. & DUBLIN--(BUSINESS WIRE)--Jun. 21, 2021-- Arrowhead Pharmaceuticals Inc.
- Arrowhead to receive $40 million upfront payment - Horizon to receive a worldwide exclusive license for an investigational short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase (XDH) PASADENA, Calif. & DUBLIN--(BUSINESS WIRE)--Jun. 21, 2021-- Arrowhead Pharmaceuticals Inc.